Aerie Surges Over 60% After Eyecare Drug Meets Primary Endpoint

Shares of Aerie Pharmaceuticals surged after the company said a late-stage study of Roclatan, its eye drop combination designed to lower intraocular pressure in patients with glaucoma or ocular hypertension, met its primary endpoint.